Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGWP.L Regulatory News (GWP)

  • There is currently no data for GWP

Blocklisting Application

17 Feb 2011 17:47

RNS Number : 4535B
GW Pharmaceuticals PLC
17 February 2011
 



 

GW Pharmaceuticals PLC ("GW Pharmaceuticals")

 

BLOCKLISTING APPLICATION

 

Porton Down, UK, 17 February 2011: GW Pharmaceuticals (AIM: GWP) hereby provides notification that application has today been made to the London Stock Exchange for admission to trading on AIM of three blocks of new ordinary shares of 0.1p each.

These new ordinary shares will be issued from time to time pursuant to the exercise of employee share options under the GW Pharmaceuticals share options schemes, as follows:

200,000 new ordinary shares for issue by the GW Pharmaceuticals Approved Share Option Scheme 2001.

400,000 new ordinary shares for issue by the GW Pharmaceuticals Executive Share Option Scheme.

600,000 new ordinary shares for issue by GW Pharmaceuticals Long Term Incentive Plan.

On exercise the shares will be issued credited as fully paid and will rank pari passu with the existing ordinary shares in issue.

It is expected that such admission will become effective on 23 February 2011.

 

 

For further information, please contact:

 

GW Pharmaceuticals PLC +44 (0)1980 557 000

Adam George, Company Secretary

 

Peel Hunt LLP (Nominated Adviser)

James Steel/Vijay Barathan +44 (0) 20 7418 8900

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
LISDKODQOBKDABD
Date   Source Headline
25th Nov 20097:02 amRNSPatient Recruitment Completed for Sativex Study
25th Nov 20097:00 amRNSFinal Results
23rd Nov 20097:00 amRNSPositive Sativex Results in Cancer Pain
4th Nov 200912:15 pmRNSNotice of Results
30th Oct 20094:43 pmRNSBlocklisting Interim Review
30th Oct 20093:41 pmRNSTotal Voting Rights
17th Sep 20094:40 pmRNSSecond Price Monitoring Extn
17th Sep 20094:35 pmRNSPrice Monitoring Extension
17th Sep 20097:00 amRNSUpdate on cannabinoid pipeline
14th Sep 20097:00 amRNSResults from two clinical studies of Savitex(R)
10th Sep 20097:00 amRNSRodman and Renshaw Conference
18th Aug 20094:23 pmRNSHolding(s) in Company
18th Aug 20094:18 pmRNSTotal Voting Rights
6th Aug 20097:00 amRNSRe Agreement
28th Jul 200911:10 amRNSDirector/PDMR Shareholding
16th Jul 20097:00 amRNSManufacturing Licence Received for Sativex
26th Jun 20098:41 amRNSDirector/PDMR Shareholding
24th Jun 20099:19 amRNSDirector/PDMR Shareholding
16th Jun 20097:00 amRNSGW Expands Cannabinoid Research
15th Jun 20095:46 pmRNSDirector/PDMR Shareholding
2nd Jun 20097:00 amRNSHolding(s) in Company
1st Jun 20094:12 pmRNSNotification of Interests of Directors
21st May 20094:00 pmRNSDirector/PDMR Shareholding
20th May 20097:01 amRNSGW Files Sativex? Regulatory Submission
20th May 20097:00 amRNSInterim Results
20th Apr 20093:20 pmRNSNotice of Results
1st Apr 20097:00 amRNS?8m Milestone Payment from Almirall
31st Mar 20097:00 amRNSBlocklisting Interim Review
31st Mar 20097:00 amRNSTotal Voting Rights
30th Mar 200910:11 amRNSDirector/PDMR Shareholding
27th Mar 20094:51 pmRNSDirector/PDMR Shareholding
13th Mar 20099:34 amRNSNotification of Interests of Directors
11th Mar 20091:12 pmRNSPositive Outcome of Sativex Phase III MS Study
2nd Mar 20095:38 pmRNSDirector/PDMR Shareholding
24th Feb 20097:00 amRNSClinical Trial Update
16th Jan 20095:27 pmRNSDirector/PDMR Shareholding
14th Jan 20092:05 pmRNSResult of AGM
2nd Dec 20085:50 pmRNSDirector/PDMR Shareholding
18th Nov 20087:00 amRNSFinal Results
24th Oct 20084:47 pmRNSSecond Price Monitoring Extn
24th Oct 20084:37 pmRNSPrice Monitoring Extension
22nd Oct 200811:00 amRNSNotice of Results
10th Oct 20084:42 pmRNSPrice Monitoring Extension
1st Oct 20087:00 amRNSTrial Completes Recruitment
8th Sep 20087:00 amRNSResearch Update
18th Jul 20084:38 pmRNSDirector/PDMR Shareholding
24th Jun 20083:36 pmRNSBlocklisting Interim Review
24th Jun 20083:32 pmRNSBlocklisting Interim Review
24th Jun 20083:27 pmRNSBlocklisting Interim Review
24th Jun 20083:22 pmRNSBlocklisting Interim Review

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.